Lewis Cantley - Agios Pharm Director
| AGIO Stock | USD 55.54 0.92 1.68% |
Director
Dr. Lewis Clayton Cantley, Ph.D., is no longer Director of Agios Pharmaceuticals, Inc., effective December 31, 2017. Dr. Cantley has served as a director of the Cancer Center at Weill Cornell Medical College and New YorkPresbyterian Hospital since October 2012. Prior to that, from 1992 to 2012, Dr. Cantley was a professor of systems biology at Harvard Medical School and chief of the division of Signal Transduction at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School in Boston. From 2007 to 2012, Dr. Cantley also served as director of the Cancer Center at Beth Israel Deaconess Medical Center. Dr. Cantley is a member of the American Academy of Arts and Sciences and the National Academy of Sciences, and serves on the editorial boards of the journals Cell and the Journal of Cell Biology. He currently serves on the board of directors of the American Association of Cancer Research and Hope Foundation for Cancer Research, nonprofit organizations that promote cancer research. Dr. Cantley is the recipient of the 2005 Pezcoller FoundationAmerican Association for Cancer Research International Award for Cancer Research, for his leadership in the field of signal transduction, including the discovery of the phosphatidylinositol3kinase signaling pathway since 2007.
| Age | 75 |
| Tenure | 17 years |
| Professional Marks | Ph.D |
| Address | 88 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 649 8600 |
| Web | https://www.agios.com |
Agios Pharm Management Efficiency
The company has return on total asset (ROA) of (0.1818) % which means that it has lost $0.1818 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5366 %, meaning that it created $0.5366 on every $100 dollars invested by stockholders. Agios Pharm's management efficiency ratios could be used to measure how well Agios Pharm manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.47. At this time, Agios Pharm's Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Non Currrent Assets Other is likely to grow to about 4.3 M, while Total Assets are likely to drop about 752.6 M.Similar Executives
| Found 2 records | DIRECTOR Age | ||
| Michael Landsittel | Blueprint Medicines Corp | 52 | |
| Stephen Donnelly | Kalvista Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.54 | ||||
| Return On Asset | -0.18 |
Agios Pharm Leadership Team
Elected by the shareholders, the Agios Pharm's board of directors comprises two types of representatives: Agios Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agios. The board's role is to monitor Agios Pharm's management team and ensure that shareholders' interests are well served. Agios Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agios Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DSc FRSC, CoFounder Board | ||
| Dr DACVP, Consultant | ||
| Sarah MD, Chief Development | ||
| James Burns, Corporate Officer | ||
| Clive Patience, Chief Officer | ||
| ShinSan Su, CoFounder Board | ||
| Brian MBA, CEO Director | ||
| Christopher Taylor, Vice Communications | ||
| T Washburn, Principal Officer | ||
| Craig MD, CoFounder Board | ||
| Cecilia Jones, Chief Officer | ||
| Richa Poddar, Chief Officer | ||
| Lewis Cantley, Co-Founder, Director, Member of Scientific Advisory Board and Member of Science and Technology Committee | ||
| Steven Vickers, Vice Sales | ||
| Tsveta Milanova, Chief Officer |
Agios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agios Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.54 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 20.51 % | ||||
| Operating Margin | (11.47) % | ||||
| Current Valuation | 2.22 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Shares Owned By Insiders | 1.50 % | ||||
| Shares Owned By Institutions | 98.50 % | ||||
| Number Of Shares Shorted | 4.34 M | ||||
| Price To Earning | 1.26 X |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.85 | TCHH | Trustcash Holdings | PairCorr |
| 0.76 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.7 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.61 | ME | 23Andme Holding | PairCorr |
| 0.6 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.